MetaCap

Envista Holdings Corporation (NVST)

NYSE: NVSTHealth CareMedical/Dental InstrumentsUSD

22.91-0.36 (-1.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVST stock chart

Technical analysis

Key statistics

All statistics
52-week range
19.67 – 30.42
Day range
22.77 – 23.76
Volume / Avg
2.31M / 2.87M
Beta
—

52-week range

$19.67$30.42

NVST stock today

Envista (NVST) closed at $22.91 on Nov 20, down 1.55% (-$0.36), versus the S&P 500's 3.70% decline. Shares are 24.7% below their 52-week high of $30.42, set on Feb 11, 2026 and 16.5% above the 52-week low of $19.67, in the middle of the past year's range. NVST is up 5.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 15.2%.

At 6.0x trailing earnings, Envista trades below the peer-group median of 69.7x. Its forward P/E of 13.7x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Envista

Company profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products.

Industry
Medical/Dental Instruments
CEO
Mr. Paul A. Keel
Headquarters
Brea, CA
Employees
12,000
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Envista generated $2.72 billion in revenue, up 8.3% from fiscal 2024. Net income was $47.0 million, for a net margin of 1.7% versus a median of 1.7% in the prior 5 years. Gross margin was 54.7% (flat year over year) and operating margin 7.9%.

Envista annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.72B$2.51B$2.57B$2.57B$2.51B
Growth+8.32%-2.18%-0.10%+2.40%+30.06%
Net income$47.00M$-1.12B$-100.20M$243.10M$340.50M
EPS (diluted)$0.28$-6.50$-0.60$1.37$1.92

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$28.92+26.23%

  • Strong buy 2
  • Buy 5
  • Hold 8
  • Sell 0
  • Strong sell 0

Target range

Low $23.00High $32.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$3.11 vs $0.35
Surprise
+788.57%

NVST news

All NVST news

Envista peers

Health Care sector
NVST peer companies
CompanyPrice% ChgMarket capCompare
HTFLHeartflow Inc.46.69+4.62%$4.10Bvs NVST
PLSEPulse Biosciences Inc45.55+2.57%$3.35Bvs NVST
STVNStevanato Group S.p.A.15.65-1.76%$4.27Bvs NVST
IRTCiRhythm Holdings Inc.94.72+0.51%$3.18Bvs NVST
ICUIICU Medical Inc.172.52-1.84%$4.31Bvs NVST
MMEDMiniMed Group Inc.16.01-1.54%$4.50Bvs NVST
ATRCAtriCure Inc.55.39+2.37%$2.82Bvs NVST
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs NVST

Indexes, lists and sector

Envista stock FAQ

What is Envista's stock price today?

NVST last traded at $22.91 as of Nov 20, 4:00 PM EST, down 1.55% on the day. Prices are delayed at least 15 minutes.

What is NVST's P/E ratio?

NVST trades at a trailing P/E ratio of 5.95 and a forward P/E of 13.68, compared with a median of 69.7 for its closest peers.

Who is Envista's CEO?

Mr. Paul A. Keel is the chief executive officer of Envista Holdings Corporation, which has about 12,000 employees.

What is the NVST 52-week high?

The 52-week high for NVST is $30.42 and the 52-week low is $19.67. The stock is currently 24.7% below its high.

Compare NVST